US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by NewAmsterdam Pharma N.V.

< Previous 1 2 Next >
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma to Host Investor Day on August 5, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
News headline image
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
< Previous 1 2 Next >